Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerGiannis Mountzios, Petros Christopoulos, Johannes Krisam et al.|ESMO Open|2021Cited by 93
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, G. Koumakis, Georgia-Angeliki Koliou et al.|ESMO Open|2020Cited by 38